GPR30 promotes prostate stromal cell activation via suppression of erα expression and its downstream signaling pathway

Endocrinology

Volumn 157, Issue 8, 2016, Pages 3023-3035

  Jia, Bona ^a   Gao, Yu ^a   Li, Mingming ^a   Shi, Jiandang ^a   Peng, Yanfei ^b   Du, Xiaoling ^a   Klocker, Helmut ^c   Sampson, Natalie ^c   Shen, Yongmei ^a   Liu, Mengyang ^d   Zhang, Ju ^a  

^a NANKAI UNIVERSITY   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA ACTIN; CALPONIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FIBROBLAST ACTIVATION PROTEIN; G PROTEIN COUPLED RECEPTOR 30; HERMES ANTIGEN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MYOSIN HEAVY CHAIN 11; MYOSIN HEAVY CHAIN BETA; PROTEIN; SMOOTH MUSCLE 22 ALPHA PROTEIN; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA, HUMAN; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN;

ARTICLE; CANCER ASSOCIATED FIBROBLAST; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONDITIONED MEDIUM; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FIBROBLAST; GENE OVEREXPRESSION; GENE SWITCHING; HUMAN; HUMAN TISSUE; LNCAP CELL LINE; MALE; MOLECULAR BIOLOGY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; STEM CELL; STROMA CELL; UPREGULATION; WOUND HEALING; CANCER STEM CELL; CELL CULTURE; CELL TRANSFORMATION; CYTOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE;

CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DOWN-REGULATION; ESTROGEN RECEPTOR ALPHA; FIBROBLASTS; HUMANS; MALE; NEOPLASTIC STEM CELLS; PROSTATE; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 84982792212     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2016-1035     Document Type: Article

References (52)

1. Clark AK, Taubenberger AV, Taylor RA, et al. A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer. Biomaterials. 2013;34:4777-4785.
2. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer. 2003;107:1-10.
3. Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer. 2012;19: R187-R204.
4. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; 6:392- 401.
5. Ayala G, Tuxhorn JA, Wheeler TM, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003;9:4792- 4801.
6. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002;8:2912-2923.
7. Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R. Tumorstroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol. 2010;21:26-32.
8. Tripathi M, Billet S, Bhowmick NA. Understanding the role of stromal fibroblasts in cancer progression. Cell Adh Migr. 2012;6:231-235.
9. Micke P, Ostman A. Tumour-stroma interaction: Cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer. 2004;45(suppl 2):S163-S175.
10. Williams G. Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-alpha and GPER signalling. Mol Cell Endocrinol. 2012;351:269-278.
11. Madar S, Brosh R, Buganim Y, et al. Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis. 2009;30:20-27.
12. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007; 449:557-563.
13. Mishra PJ, Humeniuk R, Medina DJ, et al. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008;68:4331-4339.
14. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinomaassociated fibroblasts. Cancer Res. 2007;67:10123-10128.
15. Montie JE, Pienta KJ. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology. 1994;43:892-899.
16. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Differentiation. 2002;70:473-485.
17. Ho S-M, Leung Y-K, Chung I. Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer. Ann NY Acad Sci. 2006;1089:177-193.
18. Prossnitz ER, Barton M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaqlandins Other Lipid Mediat. 2009;89:89-97.
19. Yu L, Shi J, Cheng S, et al. Estrogen promotes prostate cancer cell migration via paracrine release of ENO1 from stromal cells. Mol Endocrinol. 2012;26:1521-1530.
20. Yu L, Wang CY, Shi J, et al. Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostatic stromal cells. Endocrinology. 2011; 152:773-781.
21. Slavin S, Yeh CR, Da J, et al. Estrogen receptor ô in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3. Carcinogenesis. 2014;35:1301-1309.
22. Pupo M, Vivacqua A, Perrotta I, et al. The nuclear localization signal is required for nuclear GPER translocation and function in breast cancer-associated fibroblasts (CAFs). Mol Cell Endocrinol. 2013; 376:23-32.
23. De Francesco EM, Pellegrino M, Santolla MF, et al. GPER mediates activation of HIF1/VEGF signaling by estrogens. Cancer Res. 2014; 74:4053- 4064.
24. Zhang Z, Wang L, Mei M, et al. Both nongenomic and genomic effects are involved in estradiol's enhancing the phenotype of smooth muscle cells in cultured prostate stromal cells. Prostate. 2010;70:317-332.
25. Li F, Yu X, Szynkarski CK, et al. Activation of GPER induces differentiation and inhibition of coronary artery smooth muscle cell proliferation. PloS One. 2013;8:e64771.
26. Cronauer MV, Eder IE, Hittmair A, et al. A reliable system for the culture of human prostatic cells. In Vitro Cell Dev Biol Anim. 1997; 33:742-744.
27. Corvin S, Boesch S, Maneschg C, Radmayr C, Bartsch G, Klocker H. Effect of heat exposure on viability and contractility of cultured prostatic stromal cells. Eur Urol. 2000;37:499-504.
28. Webber MM, Trakul N, Thraves PS, et al. A human prostatic stromal myofibroblast cell line WPMY-1: A model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis. 1999;20:1185-1192.
29. Zhou Y, Xiao XQ, Chen LF, et al. Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats. Asian J Androl. 2009;11:451-459.
30. Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst. 2012;104:1320-1334.
31. Kim W, Barron DA, San Martin R, et al. RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation. Proc Natl Acad Sci USA. 2014;111:16389-16394.
32. Tsai H-W, Katzenellenbogen JA, Katzenellenbogen BS, Shupnik MA. Protein kinase A activation of estrogen receptor ô transcription does not require proteasome activity and protects the receptor from ligand-mediated degradation. Endocrinology. 2004;145:2730-2738.
33. Broselid S, Berg KA, Chavera TA, et al. G protein-coupled receptor 30 (GPR30) forms a plasma membrane complex with membraneassociated guanylate kinases (MAGUKs) and protein kinase A-anchoring protein 5 (AKAP5) that constitutively inhibits cAMP production. J Biol Chem. 2014;289:22117-22127.
34. Ding Q, Gros R, Limbird LE, Chorazyczewski J, Feldman RD. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. Am J Physiol Cell Physiol. 2009;297:C1178-C1187.
35. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation. 2001;104:2525-2532.
36. Suzuki J, Takayama K, Mitsui F, et al. In situ interleukin-6 transcription in embryonic nonmuscle myosin heavy chain expressing immature mesenchyme cells of cardiac myxoma. Cardiovasc Pathol. 2000;9:33-37.
37. Shao R, Shi J, Liu H, et al. Epithelial-to-mesenchymal transition and estrogen receptor ô mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia. Prostate. 2014;74: 970-982.
38. Verfaillie CM. Adult stem cells: Assessing the case for pluripotency. Trends Cell Biol. 2002;12:502-508.
39. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44 ô prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006;25:1696-1708.
40. Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y. G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Commun. 2006;346:904-910.
41. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 2005;146:624-632.
42. Revankar CM, Mitchell HD, Field AS, et al. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol. 2007;2:536-544.
43. Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17ô-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res. 2010;70: 6036- 6046.
44. Ariazi EA, Brailoiu E, Yerrum S, et al. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 2010;70:1184-1194.
45. Gao F, Ma X, Ostmann AB, Das SK. GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor ô (ERô) phosphorylation signals. Endocrinology. 2011;152:1434-1447.
46. Lim A, Shin K, Zhao C, Kawano S, Beachy PA. Spatially restricted Hedgehog signalling regulates HGF-induced branching of the adult prostate. Nat Cell Biol. 2014;16:1135-1145.
47. Zhang HZ, Bennett JM, Smith KT, Sunil N, Haslam SZ. Estrogen mediates mammary epithelial cell proliferation in serum-free culture indirectly via mammary stroma-derived hepatocyte growth factor. Endocrinology. 2002;143:3427-3434.
48. Yeh CR, Slavin S, Da J, et al. Estrogen receptor ô in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment. Mol Cancer. 2016;15:7.
49. DiNatale BC, Schroeder JC, Perdew GH. Ah receptor antagonism inhibits constitutive and cytokine inducible IL6 production in head and neck tumor cell lines. Mol Carcinog. 2011;50:173-183.
50. Chan QKY, Lam HM, Ng CF, et al. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G2 cell-cycle arrest. Cell Death Differ. 2010;17:1511-1523.
51. Lam HM, Ouyang B, Chen J, et al. Targeting GPR30 with G-1: A new therapeutic target for castration-resistant prostate cancer. Endocr Relat Cancer. 2014;21:903-914.
52. Niu Y, Altuwaijri S, Lai KP, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA. 2008;105:12182-12187.